
<!DOCTYPE html>
<html>
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>arrhythmias</title>
    <style>
        body { max-width: 800px; margin: 40px auto; padding: 0 20px; font-family: -apple-system, system-ui, sans-serif; }
        pre { overflow-x: auto; }
        table { border-collapse: collapse; width: 100%; }
        th, td { border: 1px solid #ddd; padding: 8px; text-align: left; }
        details { margin: 20px 0; padding: 10px; background: #f5f5f5; border-radius: 4px; }
    </style>
</head>
<body>
    <h1>Atrial Fibrillation Management</h1>
<h2>Question</h2>
<p>A 72-year-old woman with newly diagnosed atrial fibrillation has a CHA₂DS₂-VASc score of 4. She has normal renal function and no history of bleeding. Which is the most appropriate anticoagulation strategy?</p>
<h2>Options</h2>
<table>
<thead>
<tr>
<th>Option</th>
<th>Description</th>
</tr>
</thead>
<tbody><tr>
<td>A)</td>
<td>No anticoagulation needed</td>
</tr>
<tr>
<td>B)</td>
<td>Aspirin 81mg daily</td>
</tr>
<tr>
<td>C)</td>
<td>Warfarin with target INR 2-3</td>
</tr>
<tr>
<td>D)</td>
<td>Direct oral anticoagulant (DOAC)</td>
</tr>
</tbody></table>
<details>
<summary>View Answer</summary>

<h2>Correct Answer</h2>
<p>D</p>
<h2>Explanation</h2>
<ul>
<li>CHA₂DS₂-VASc score ≥2 indicates high stroke risk requiring anticoagulation</li>
<li>DOACs are preferred over warfarin in non-valvular AF due to:<ul>
<li>Lower intracranial bleeding risk</li>
<li>No need for regular INR monitoring</li>
<li>Fewer drug-drug interactions</li>
<li>More predictable anticoagulation effect</li>
</ul>
</li>
</ul>
<h2>References</h2>
<ul>
<li>2019 AHA/ACC/HRS Focused Update of the 2014 Guidelines for AF Management</li>
<li>2020 ESC Guidelines for AF Management</details></li>
</ul>

</body>
</html>